ADMA Biologics Inc - Common Stock (ADMA)

NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities laws.

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The law firm of Kirby McInerney LLP continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ADMA To Contact Him Directly To Discuss Their Options

Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) on behalf of investors concerning the Company’s possible violations of federal securities laws.

RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today addressed a report issued on March 24, 2026 by Culper Research (the “Short Report”), a firm that has published similarly negative “research reports” regarding public companies after taking short positions in the stock. The Short Report discloses that Culper Research holds a short position in ADMA. ADMA, and its Board of Directors takes seriously its obligations to fairly and accurately report its operating and financial results and make all public disclosures in accordance with the rules and regulations of the U.S. Securities and Exchange Commission and in accordance with the standards of U.S. GAAP. The Short Report, by contrast, appears premised on speculative assertions derived from unidentified and unreliable sources and contains numerous misleading, false and inaccurate statements. Despite the conjecture pervading the Short Report, ADMA is taking appropriate steps to review the assertions.

RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase (“ASR”) agreement with JPMorgan Chase Bank, National Association (“JPMorgan”). The initiative underscores the Company’s strong financial position, durable free cash flow profile and confidence in its long-term growth trajectory.

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth

Conference Call Scheduled for February 25, 2026, at 4:30 p.m. ET

FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 9:45 a.m. PT.

3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 

Conference Call Scheduled for November 5, 2025, at 4:30 p.m. ET

2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item

Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET

1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase

Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END